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Tumor suppressor genes (TSGs) are often concom-
itantly lost or mutated in human cancers and
have been shown to act synergistically to promote
tumorigenesis. In addition to genomic altera-
tions, posttranscriptional regulation by microRNAs
(miRNAs) represents another mechanism by which
TSG expression is dysregulated in cancers.
Although miRNAs that target critical TSGs such as
PTEN or p53 have been identified, little is known
about miRNAs that concomitantly regulate both
these key TSGs. In this study, we characterize
microRNA 518c* (miR-518c*) and miR-638 as dual
PTEN- and p53-targeting miRNAs that are upre-
gulated in multiple human cancers. We focus on
miR-638 and show that it associates independently
with these two tumor suppressor transcripts as
well as BRCA1, a known miR-638 target. We find
that miR-638 overexpression promotes tumori-
genesis and demonstrate cooperativity between
miR-638 and its host gene Dnm2, suggesting
that the Dnm2 locus encodes two distinct onco-
genic components that play important roles in
tumorigenesis.INTRODUCTION
PTEN (phosphatase and tensin homolog deleted on chromo-
some 10) is one of the most frequently lost and mutated tumor
suppressor genes (TSGs) in a wide spectrum of human can-
cers. PTEN encodes a plasma membrane lipid phosphatase
that functions predominantly as an inhibitor of the proto-onco-
genic phosphatidylinositol 3-kinase-AKT signaling pathway
that regulates cell growth and survival (Song et al., 2012).
In vivo models that demonstrate that heterozygous PTEN
loss and an even subtler reduction in its expression leads to714 Cell Reports 8, 714–722, August 7, 2014 ª2014 The Authorsan increased incidence of spontaneous tumors in multiple
tissue types provide further support for the key tumor-sup-
pressive function of PTEN (Berger et al., 2011; Di Cristofano
et al., 1998).
p53, epitomized as the ‘‘guardian of the genome,’’ is one of the
most-studied and frequently mutated or deleted TSGs. It en-
codes a transcription factor that regulates the expression of
target genes involved in DNA repair, cell-cycle arrest, apoptosis,
senescence, and other cellular processes (Vousden and Lane,
2007). Additional evidence for the importance of p53 in tumori-
genesis was provided by mouse models that demonstrated
that either the heterozygous or homozygous loss of p53 leads
to an increased risk for cancer in a variety of tissues (Donehower
et al., 1992).
The functions of these two TSGs are intricately intertwined.
PTEN has been shown to physically associate with p53, regulate
its DNA-binding activity, and protect it from Mdm2-medi-
ated degradation (Freeman et al., 2003; Mayo et al., 2002).
Conversely, p53 has been reported to regulate PTEN transcrip-
tion (Stambolic et al., 2001). Several studies have examined
the functional relevance of this reciprocal cooperation between
PTEN and p53. Chen et al. found that although Pten inactivation
leads to nonlethal invasive cancer in the prostate after long la-
tency and p53 inactivation did not lead to cancer, combined
Pten and p53 inactivation resulted in invasive prostate cancer
in mice with lethality by 7months (Chen et al., 2005). Puzio-Kuter
et al. observed that Pten or p53 single-mutant mice did not
develop bladder tumors up to 1 year of age, but inactivation of
both genes led to large tumors with 100% penetrance by
6 months (Puzio-Kuter et al., 2009). Andjelkovic et al. found
that the loss of both these genes occurred frequently in patients
with non-small-cell lung cancer, was associated with increased
lymph node invasion, and reduced survival (Andjelkovic et al.,
2011).
Collectively, these reports suggest that these two TSGs may
crosstalk at multiple levels and that their compound inactiva-
tion is an event that is strongly selected for in human cancers.
This in turn led us to hypothesize that mechanisms that
induce the concomitant downregulation of both these tumor
suppressors may play key roles in cancer development. Aside
from genetic deletions or mutations that result in the heterozy-
gous or homozygous loss of PTEN or p53 function, other
mechanisms that contribute to the dysregulation of PTEN or
p53 expression in cancers include epigenetic silencing, tran-
scriptional repression, posttranslational modifications, and
posttranscriptional regulation by microRNAs (miRNAs) (Song
et al., 2012).
miRNAs are small noncoding RNAs that modulate gene
expression by binding to specific recognition sites on target
transcripts (Bartel and Chen, 2004). Several studies have
identified miRNAs that target either the PTEN or p53 tran-
scripts (Hermeking, 2012; Tay et al., 2013). However, little
is known about miRNAs that concomitantly regulate both
these key TSGs. In this study, we characterize miR-518c*
and miR-638 as dual PTEN and p53-targeting miRNAs.
We find that overexpression of miR-638, which is encoded
in the oncogenic Dnm2 locus, promotes tumorigenic pro-
perties, including cell proliferation, migration, and invasion.
These data suggest that the Dnm2 gene comprises a two-hit
oncogenic locus that plays an important role in cancer
progression.
RESULTS
Identification of Potential Dual PTEN and p53-Targeting
miRNAs
We first performed miRNA target-prediction analyses to iden-
tify miRNAs that may target both full-length PTEN and p53
transcripts (Table S1). Because the combined loss of PTEN
and p53 has been shown to promote prostate cancer metas-
tasis (Abou-Kheir et al., 2011), we next examined the expres-
sion profiles of these miRNAs in prostate cancer. Of the 51
predicted dual-targeting miRNAs, 14 were upregulated in hu-
man metastatic prostate cancer samples (Figures 1A and
S1A). We selected miR-518c*, miR-584, and miR-638 for
experimental validation because their expression levels were
also increased in colon and kidney cancers (Figures S1B
and S1C), additional cancers with frequent loss of PTEN
and p53.
Next, we investigated their effect on endogenous PTEN
and p53 levels. Overexpression of miR-518c*, miR-584, and
miR-638 resulted in a significant decrease in PTEN protein
levels in both HCT116 colon cancer and U2OS osteosar-
coma cell lines that express wild-type PTEN and p53
(Figures 1B and 1C). This was accompanied by a concomitant
increase in Akt activation. Similarly, miR-518c*, miR-584,
and miR-638 reduced p53 protein levels and decreased
expression of p21, a downstream effector of p53 (Figures 1D
and 1E).
Direct Regulation of the PTEN and p53 Transcripts by
miR-518c* and miR-638
Because PTEN and p53 have been shown to reciprocally cor-
egulate each other as discussed above, we next investigated
whether these observed effects were due to bona fide miRNA
targeting or were alternatively a result of protein-mediated
crosstalk. PC3 prostate cancer cells were selected as an
ideal model system for this purpose because they are PTENnull and p53 null and do not express detectable levels of
either transcript or protein (Isaacs et al., 1991; Vlietstra et al.,
1998).
miR-518c*, miR-584, and miR-638 have predicted target sites
in the 50 UTR and/or coding region of PTEN and p53 (Fig-
ure S2A). To examine whether these predictions represented
functional binding sites, we first constructed vectors expressing
the 50 UTR plus coding region of PTEN and p53 and cotrans-
fected them into PC3 cells with miR-518c*, miR-584, or miR-
638. Overexpression of miR-518c* and miR-638 significantly
downregulated the expression of both 50 UTR plus coding
sequence (CDS) constructs, suggesting that their effect on
PTEN and p53 is partly 30 UTR independent (Figures 2A and
2B). Although miR-584 also downregulated expression of exog-
enous PTEN, it did not have a significant effect on exogenous
p53 expression. This suggests that the predicted miR-584 mi-
croRNA response elements (MREs) in p53 are not bona fide
MREs and that miR-584’s effect on endogenous p53 is most
likely indirect.
Next, we generated luciferase reporter constructs harboring
the various fragments (50 UTR, CDS [ATG], and 30 UTR) of the
PTEN and p53 transcripts. Overexpression of miR-638 resulted
in a modest but significant decrease in expression of the
PTEN-50 UTR, CDS (ATG), and 30 UTR reporters, as well as
the p53-CDS (ATG) and 30 UTR reporters (Figures 2C and
2D). It did not affect the p53-50 UTR reporter. These results
are consistent with the location of predicted MREs on these
transcripts.
miR-518c* overexpression reduced expression of the PTEN-
CDS (ATG) and p53-50 UTR constructs, consistent with the
location of several predicted MREs (Figures 2C and 2D). How-
ever, it did not affect expression of the PTEN-50 UTR or p53-
CDS (ATG) reporters, suggesting that these predictions were
not bona fide MREs. Furthermore, it significantly reduced
expression of the PTEN-30 UTR reporter, suggesting the exis-
tence of additional MREs.
miR-584 overexpression reduced expression of the PTEN-50
UTR and PTEN-CDS (ATG) constructs, consistent with the
location of its predicted PTEN MREs (Figure 2C). Its ability to
reduce expression of the PTEN-30 UTR reporter suggests that
it may also have additional target sites there. Consistent with
our earlier observations, it did not have a significant effect on
any of the p53 reporters. Taken together, these data provide
evidence that PTEN is a bona fide target of miR-584 and suggest
that bothmiR-638 andmiR-518c* are dualPTEN and p53-target-
ing miRNAs.
miR-638 Independently Targets PTEN, p53, and BRCA1
Intriguingly, BRCA1 has been identified as a target of miR-638
(Nicoloso et al., 2010). BRCA1 is an important TSG involved in
DNA damage repair and the maintenance of genomic stability,
and the BRCA1 protein has been shown to reciprocally coregu-
late p53 and Akt signaling (Altiok et al., 1999; Zhang et al., 1998).
To disentangle potential miRNA-mediated regulation from pro-
tein-dependent crosstalk, we performed biotinylated miRNA
pull-downs to examine the direct association of miR-638 with
each of these tumor suppressor transcripts. We found that
PTEN, p53, and BRCA1 transcripts were enriched in miR-638Cell Reports 8, 714–722, August 7, 2014 ª2014 The Authors 715
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Figure 1. Identification of Potential Dual PTEN and p53-Targeting miRNAs
(A) Expression of miR-584, miR-638, and miR-518c* in primary and metastatic prostate cancer compared to normal prostate.
(B and C) Effect of miR-584, miR-638, or miR-518c* overexpression on endogenous PTEN and P-Akt expression. Representative western blots are shown in (B),
and quantitation of all blots is shown in (C).
(D and E) Effect of miR-584, miR-638, or miR-518c* overexpression on endogenous p53 and p21 expression. Representative western blots are shown in (D), and
quantitation of all blots is shown in (E).
(C and E) Mean ± SD. (A, C, and E) *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S1 and Table S1.





Figure 2. miR-638 and miR-518c* Directly
Target PTEN and p53
(A) Expression of exogenous PTEN and P-Akt in
PC3 cells after cotransfection of the negative
control (NC), miR-518c*, miR-584, or miR-638
with a plasmid construct expressing only the
PTEN 50 UTR plus CDS.
(B) Expression of exogenous p53 and p21 in PC3
cells after cotransfection of the NC, miR-518c*,
miR-584, or miR-638 with a plasmid construct
expressing only the p53 50 UTR plus CDS.
(C and D) Luciferase validation assays demon-
strating the effect of miR-518c*, miR-584, or miR-
638 overexpression on the 50 UTR, 30 UTR, and
ATG-less CDS fragments of (C) PTEN and (D) p53
relative to the NC in PC3 cells.
(E) Expression of PTEN, p53, and BRCA1 mRNAs
in biotinylated miR-638 pull-downs from U2OS
cells.
Mean ± SD; n R 4. *p < 0.05; **p < 0.01; ***p <
0.001. See also Figure S2.pull-downs, suggesting that they all independently associate
with miR-638 (Figure 2E).
miR-638 was shown to regulate BRCA1 by binding to a single
MRE in its coding region. To identify the specific MREs respon-
sible for its regulation of PTEN and p53, we cloned the predicted
miR-638 MREs downstream of a luciferase reporter. Overex-Cell Reports 8, 714–72pression of miR-638 resulted in a modest
but significant reduction in the levels of all
these reporter constructs (Figure S2B),
except for the PTEN-C2 MRE, which ap-
peared to have a cell-type-dependent
effect.
Although miRNA binding to MREs in
the coding regions and 30 UTRs of target
genes generally results in the repression
of gene expression, miRNA binding to 50
UTRs may enhance translation (Ørom
et al., 2008). To investigate the potential
context-dependent effect of the miR-
638 50 UTR and CDS MREs, we gener-
ated reporter constructs with the 50 UTR
MREs upstream of the luciferase reporter
and the CDS MREs just upstream and in
frame with the luciferase stop codon.
Overexpression of miR-638 resulted in a
modest but significant reduction in the
levels of these PTEN 501, 503, C1, and
p53 C1 MRE reporter constructs in PC3
cells (Figure S2C). These data are consis-
tent with our previous observations when
they were cloned into the luciferase 30
UTR and suggest that these MREs do
not function in a context-dependent
manner. However, we no longer saw a
significant reduction in luciferase activity
with the PTEN 502 MRE cloned into the
luciferase 50 UTR or the PTEN C2 MRE cloned into the lucif-
erase-coding region, suggesting that these two MREs may not
be functional in their endogenous contexts.
We next performed site-directed mutagenesis of the seed
regions of the CDS and 30 UTR MREs in the luciferase reporter




Figure 3. Overexpression of miR-638 and
miR-518c* Promotes Tumorigenesis
Effect of miR-638 or miR-518c* overexpression on
cell migration (A) and invasion (B), proliferation (C),
and anchorage-independent growth (D) in vitro.
Mean ± SD; n R 4. **p < 0.01; ***p < 0.001. See
also Figure S3.fragments. Mutation of the PTEN C1 and p53 301 MREs resulted
in complete rescue of the miR-638-mediated suppression of the
respective luciferase constructs, whereas mutation of the PTEN
301 and p53 C1 MREs resulted in a partial but significant rescue
of the respective luciferase constructs (Figure S2D). These re-
sults provide further support for the functional role of these
MREs in miR-638-mediated PTEN and p53 regulation.
Overexpression of miR-638 and miR-518c* Promotes
Tumorigenesis
PTEN and p53 have been shown to function as important regu-
lators of cell migration, invasion, and proliferation. We thus
hypothesized that miR-518c* and miR-638 may be critical
modulators of these hallmarks of tumorigenesis. In vitro wound
healing and Boyden chamber assays demonstrated that overex-
pression of miR-518c* or miR-638 resulted in a significant in-
crease in both cell migration (Figures 3A, S3A, and S3B) and
invasion (Figures 3B and S3C). Additionally, miR-518c* or miR-
638 overexpression increased cell proliferation (Figure 3C) and
enhanced anchorage-independent growth in soft agar (Figures
3D, S3D, and S3E). Similar effects on target gene expression,
cell proliferation, and migration were observed with 2 nM of
transfected mimic (Figures 4A–4D). Because this amount of
transfected mimic is more representative of the fold induction
observed in cancers (Figure S3F), these data provide support718 Cell Reports 8, 714–722, August 7, 2014 ª2014 The Authorsfor the functional relevance of the upregu-
lation of these miRNAs in various patho-
physiological conditions.
We subsequently focused our attention
on miR-638 due to its ability to target
PTEN, p53, and BRCA1, and because
it had a consistently stronger effect on
enhancing tumorigenic potential in vitro.
Notably, we found that miR-638 over-
expression increased the growth of
colon cancer xenograft tumors in nude
mice (Figure S3G). Next, we determined
endogenous miR-638 expression levels
in a panel of cell lines with wild-type
PTEN, p53, and BRCA1 (Figure S4A). All
cell lines tested expressed detectable
levels of miR-638, with the highest levels
observed in U2OS and HCT116 cells. In-
hibition of endogenous miR-638 resulted
in a significant upregulation of PTEN and
p53 protein levels (Figure 4E), with a
concomitant decrease in cell prolifera-
tion, migration, and invasion (Figures 4F
and 4G). These data are complementaryto those observed in the overexpression experiments and pro-
vide further evidence for the functional role of physiological
levels of miR-638 in regulating PTEN and p53 levels.
miR-638 Is a Functionally Relevant Component of the
Oncogenic DNM2 Locus
The miR-638 precursor is located in the first intron of the DNM2
gene (Figure 5A). DNM2 is a microtubule-associated, GTP-bind-
ing protein, and recent reports have demonstrated that its over-
expression promotes growth, migration, and invasion in various
cancers (Eppinga et al., 2012; Feng et al., 2012). On this basis,
we hypothesized that the DNM2 locus may represent a two-hit
oncogenic locus that produces both the DNM2 protein and
miR-638.
To test this hypothesis, we first overexpressed miR-638 and
DNM2 independently and in combination in both HCT116 and
U2OS cells. As previously reported, DNM2 overexpression
led to an increase in cell proliferation (Figure 5B) (Feng et al.,
2012). The concurrent overexpression of both miR-638
and DNM2 significantly augmented cell growth above that
observed with either miR-638 or DNM2 alone (Figure 5B).
Next, we investigated potential cooperativity between miR-
638 knockdown and DNM inhibition. U2OS cells were selected
for proof of principle studies because they expressed the high-




Figure 4. Functional Relevance of Physiological Levels of miR-638 and miR-518c*
(A and B) Effect of miR-518c* or miR-638 overexpression (transfected at 2 nM) on endogenous PTEN and p53 expression. Representative western blots are
shown in (A) and quantitation of all blots is shown in (B).
(C and D) Effect of miR-518c* or miR-638 overexpression (transfected at 2 nM) on cell proliferation (C) and migration (D).
(E) Effect ofmiR-638 inhibition (638AS) on endogenous PTEN and p53 expression. Representative western blots are shown in the top panel, and quantitation of all
blots is shown below.
(F and G) Effect of miR-638 inhibition on cell proliferation (F), migration (G, top panel), and invasion (G, bottom panel).
Mean ± SD; nR 4. *p < 0.05; **p < 0.01; ***p < 0.001.demonstrated that the combined effect of miR-638 knockdown
and either Dynasore or MiTMAB, two small molecule inhibitors
of DNM function, led to a reduction in cell proliferation that wassignificantly greater than that observed with miR-638 knock-
down or Dynasore or MiTMAB treatment alone (Figure 5C).
These data suggest that miR-638 and the DNM2 proteinCell Reports 8, 714–722, August 7, 2014 ª2014 The Authors 719
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Figure 5. miR-638 Is Part of the Oncogenic
DNM2 Locus
(A) Schematic depicting the location of the miR-
638 precursor in the DNM2 gene.
(B) Effect of the combinatorial overexpression of
miR-638 and Dnm2 on cell proliferation.
(C) Combined effect of miR-638 knockdown and
the Dynamin inhibitors Dynasore (Dyna; left panel)
and MiTMAB (right panel) on cell proliferation in
U2OS cells.
Mean ± SD; n R 4. *p < 0.05; **p < 0.01; ***p <
0.001. See also Figure S4.represent two distinct oncogenic components encoded by the
DNM2 locus.
DISCUSSION
In this study, we examine miRNA-mediated posttranscriptional
regulation of the full-length PTEN and p53 transcripts and their
role in promoting tumorigenesis. We characterize miR-518c*
and miR-638 as PTEN and p53-targeting miRNAs and confirm
previous reports that identify BRCA1 as an additional miR-638
target (Li et al., 2012; Nicoloso et al., 2010). These miRNAs
may represent a powerful mechanism to simultaneously modu-
late levels of these key TSGs that are known to cooperate recip-
rocally to inhibit tumorigenesis.
Existing studies have focused exclusively on the 30 UTRs of
PTEN and p53 as sites for miRNA regulation. It has been shown
in both cancer cell lines and primary tumors that transcripts often
have shorter 30 UTRs in cancer cells compared to untransformed
cells and thus may be subject to less 30 UTR-dependent miRNA
regulation (Lembo et al., 2012; Mayr and Bartel, 2009). For
example, PTEN, p53, and BRCA1 have three (Lianoglou et al.,
2013), three, and seven validated alternative polyadenylation
sites, respectively. It is thus conceivable that the ability of miR-
638 and miR-518c* to bind and regulate these transcripts in a
partly 30 UTR-independent fashion may enable them to modulate
theexpressionofa larger subsetof transcript variants. Thismaybe
of particular relevance in cancer cellswith reduced30 UTR-depen-
dent miRNA regulation. Interestingly, the miR-638-binding site in
BRCA1 identified byNicolosoet al. (2010)was in its coding region.
The role of these miRNAs in tumorigenesis remains largely un-
characterized.miR-518c* is located in thechromosome19miRNA720 Cell Reports 8, 714–722, August 7, 2014 ª2014 The Authorscluster (C19MC), which is the largest hu-
man miRNA gene cluster discovered to
date (Bortolin-Cavaille´ et al., 2009). This
miRNA cluster has been reported to be
amplified in aggressive embryonal brain
andparathyroid tumors and epigenetically
reactivated through DNA demethylation in
gastric cancer (Li et al., 2009; Tsai et al.,
2009; Vaira et al., 2012). Specifically,
elevated levels of miR-518c* were re-
ported to be significantly associated
with reduced progression-free survival in
bladder carcinoma (Dyrskjøt et al., 2009).ThemiR-638 precursor is located in the first intron of the Dnm2
gene. Our data suggest that the Dnm2 locus encodes two
distinct proto-oncogenic components that play important roles
in tumorigenesis. Copy number amplifications at this locus
were observed in ovarian and uterine cancers (Figure S4B). In
accordance with this, DNM2 transcript expression was found
to be significantly elevated in multiple ovarian cancer data sets
(Figure S4C). Critically, miR-638 amplification was found to
be significantly associated with decreased patient survival in
ovarian cancer (Figure S4D). Additional studies reported that
high expression levels of miR-638 were significantly associated
with shorter overall survival in adrenocortical carcinoma (O¨zata
et al., 2011) and squamous cell lung carcinoma (Landi et al.,
2010). These data provide further support for the functional rele-
vance of miR-638 in human cancers.
Interestingly, it has been reported that miR-638 is one of
several miRNAs that is selectively packaged in membrane vesi-
cles released from cancer cells (Jaiswal et al., 2012). A very
recent study found that miR-638 was one of only three serum
miRNAs inversely associated with overall survival in patients
with nasopharyngeal carcinoma (Liu et al., 2014). Aside from
its function in a cell of origin, miR-638 may be able to regulate
gene expression in recipient cells and thus play an important
role in the intercellular regulation of cancer development.
Related work from our group and others has demonstrated
that transcripts that contain binding sites for shared miRNAs
can coregulate each other by titrating miRNA availability, thus
functioning as natural miRNA sponges or competing endoge-
nous RNAs (ceRNAs) (Tay et al., 2014). In particular, much effort
has focused on characterization of the PTEN ceRNA network.
Our study suggests that in certain conditions whereby the
abundance of PTEN, p53, and BRCA1 falls within the range for
optimal ceRNA crosstalk, their ability to sequester miR-518c*
and miR-638 may represent an additional mechanism of recip-
rocal coregulation between these TSGs. Furthermore, existing
studies that examine ceRNA crosstalk between protein-coding
transcripts have been limited exclusively to 30 UTR-dependent
regulation.We suggest that expanding ceRNA crosstalk analysis
to include 50 UTRs and coding regions of protein-coding tran-
scripts may lead to new insights into this network of competitive
miRNA-RNA interactions and to the identification of novel TSGs
or oncogenes based on their ceRNA function.
EXPERIMENTAL PROCEDURES
miRNA target prediction was performed using Rna22 (Miranda et al., 2006).
MREs and transcript fragments were cloned into psicheck2 and pcDNA3.1 ac-
cording to standard protocols. For the psicheck2 constructs, the 50 UTR frag-
mentswere cloned upstream of the luciferase-coding region, whereas theCDS
and 30 UTR fragments were cloned in the luciferase 30 UTR. Site-directedmuta-
genesis was performed according to the manufacturer’s protocols using the
QuikChange Lightning Site-Directed Mutagenesis Kit from Agilent Technolo-
gies. HCT116, U2OS, and PC3 cells were cultured under standard conditions.
miRNA mimics and inhibitors were purchased from Dharmacon. Transient
transfections were performed with 2 or 100 nM of miRNA mimic or inhibitor
with DharmaFECT 1 according to the manufacturer’s protocols. Western
blot, real-time PCR, and luciferase assays were performed as previously
described (Tay et al., 2008). Biotinylated miRNA pull-downs were performed
as previously described by Lal et al. (2011). Growth curves and soft agar assays
were performed as previously described (Tay et al., 2011). Wound healing,
transwell migration, and xenograft assays were performed according to stan-
dard protocols. All mouse work was performed in accordance with our IACUC
protocol. Invasion assays were performed using Matrigel Invasion Chambers
from BD Biosciences according to the manufacturer’s protocols.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.06.064.
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